Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.
|Videos|May 27, 2020
CMSC 2020 Day 2: Anthony Feinstein, MPhil, PhD, on Diagnosing and Treating Depression in MS
Author(s)NeurologyLive® Staff
Anthony Feinstein, MPhil, PhD, FRCP, presents his lecture titled, "Depression and MS: Diagnosing and Treating" as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
2
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis
3
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5